Event Type: Q2 FY27 Earnings Conference Call hosted by Systematix Shares & Stocks India Limited
Date and Time: Tuesday, November 17, 2026 (time not specified)
Purpose: Discussion of financial performance/financial results for Quarter-II of Financial Year 2026-27 ended September 30, 2026
Management Participants:
- Mr. Manish Dhanuka – Managing Director
- Mr. Mridul Dhanuka – Whole-Time Director
- Mr. Sunil Gupta – Chief Financial Officer
- Mr. Nishant Dalal – Vice President, Finance
- Mr. Kapil Dayya – Company Secretary
Moderator: Mr. Vishal Manchanda from Systematix Shares & Stocks India Limited
Availability of Materials: The transcript of the earnings call is available on the company's website at https://www.orchidpharma.com/investors. An audio recording was submitted via letter dated November 17, 2026.
Financial Period Discussed: Q2 FY27 (Quarter ended September 30, 2026) and H1 FY27 (Half-year ended September 30, 2026)
Key Financial Highlights:
- Q2 FY27 Revenue from operations: INR341 crores (14% YoY growth from INR299 crores in Q2 FY26)
- Q2 FY27 Gross margin: 39% (improved from 31% in Q2 FY26)
- Q2 FY27 EBITDA including other income: INR52 crores (148% YoY growth from INR21 crores)
- Q2 FY27 EBITDA margin: 15% (improved from 7%)
- Q2 FY27 Profit after tax: INR28.6 crores (vs loss of INR0.9 crores in Q2 FY26)
- Q2 FY27 EPS: INR4.77
- H1 FY27 Revenue from operations: INR645 crores (15% YoY growth from INR562 crores)
- H1 FY27 Gross margin: 36% (improved from 30%)
- H1 FY27 EBITDA: INR77 crores (148% YoY growth from INR31 crores)
- H1 FY27 EBITDA margin: 12% (improved from 6%)
- H1 FY27 Profit after tax: INR32 crores
- H1 FY27 Operating cash flow: INR118 crores
One-Time Items:
- Expected credit loss provision: INR5 crores
- Impairment loss from Dhanuka Laboratories merger: INR5 crores
Business Updates:
- Merger of Dhanuka Laboratories Limited with Orchid Pharma effective July 10, 2026 with appointed date of April 1, 2024
- AMS business quarterly EBITDA drag reduced to approximately INR1.5 crores
- EXBLIFEP royalties and licensing fees improving each quarter
- Russia license agreement: Estimated 10-year sales approximately $178 million
- Latin America license agreement: Estimated 10-year sales approximately $80 million
- European markets: Growth trajectory encouraging, UK launch expected to be significant
- Middle East and South Africa launches expected by Q1 2027
- Targeting 3-4 additional license agreements in next two quarters (Australia, Southeast Asia, Japan, other Latin American markets, North Africa)
Project Updates:
- Cefiderocol project: INR173 crores invested as of September 30, 2026
- Target commissioning: December 2026
- Validation and initial batches: January-March 2027
- Inauguration scheduled: January 18, 2027
- India launch target: Q3 2027
- 7-ACA project: Capacity of 1,000 metric tons per annum
- Commercial operations scheduled: March 2027
- Pilot technology validated, working on improving yields
Working Capital:
- Utilization reduced to INR412 crores at September 2026 from INR464 crores in March 2026
- Working capital days improved to 118 from 137
- Receivable days improved to 100 from 113
Cost Structure:
- H1 FY27 Employee expenses: INR59 crores (almost flat vs INR58 crores last year)
- H1 FY27 Other expenses: INR135 crores (increased from INR114 crores due to high power and fuel costs and higher selling expenses)
- Fuel and energy costs nearly 30% higher YoY due to Middle East war
Compliance Statement: The document contains standard regulatory compliance language but does not explicitly state that no unpublished price sensitive information (UPSI) will be shared.
Additional Notes Section
The document includes the full transcript of the earnings conference call with detailed Q&A session covering topics such as:
- EXBLIFEP manufacturing and supply arrangements
- US market status (preliminary discussions only)
- Fundraising plans (exploring with investors, no fixed timeline or mode decided)
- 7-ACA pricing stability and market conditions
- PLI scheme benefits clarity awaited
- Royalty income current run rate: $3-4 million per year
- Domestic hospital business: Working with 120+ hospitals regularly
- Product basket: 15 distinct products, 18 SKUs
- Cephalosporin market trends: Injectables showing recovery, oral products still constrained
- Gross margin sustainability dependent on product mix management
- Cefiderocol India commercialization rights at advanced stage
- Fundraising purpose: Cost overrun of 7-ACA project, debt repayment for cefiderocol, downstream product investment
No financial data attachments were included with this disclosure - the transcript contains the financial figures discussed during the call.